Cervical Cancer Preventive Vaccination
Published on Mar 02 2010, in the categories: Facts, Preventive measures, Useful info, Vaccination
Cervical cancer preventive vaccination - In this instance we will take Frace’s own Garsil’s example: Different types of viruses, the family of human papillomavirus (HPV) are the cause of cervical cancer of the uterus. Today, the Pap test (Pap smear) can detect these infections, sexually transmitted in most cases remain hidden or are benign. But these infections can also develop into precancerous lesions, and if they are not treated, cancer of the cervix uteri.
There are every year and 258 000 deaths worldwide, including 1 000 in France. Papillomaviruses present in 80% cases do not have the same carcinogenic. The most harmful is undoubtedly that of type 16 (HPV-16), implicated in 50 to 60% of cancers of the cervix. Comes second, HPV-18 which is responsible for 10% of cancers col2. Conversely, the risk of cancer among women not infected is virtually nil.
Only downside to the strategy of Pap smear screening, it involves a large number of reviews that benefit only a minority. Indeed, a maximum of 3% of women with HPV will develop cancer. Thus the development of an effective vaccine could soon lead to another prevention strategy.
A 100% protection - On September 20, 2006, the vaccine Gardasil received its European approval for placing on the market. This vaccine protects against human papillomavirus types 6, 11, 16 and 18 ,HPV 6 and 11 cause 90% of genital warts, sexually transmitted infections better known under the name of cockscomb. Several studies have measured the effectiveness of the vaccine, the principal has involved more than 12 000 women aged 16 to 26 years who were not infected by the virus.
Half received three doses of the vaccine and half received a placebo (inactive drug).After 17 months of follow-up, the first group showed no pre-cancerous lesions while they were 21 in the second group. Then, the principal investigator of the group Research on HPV at Washington University in Seattle.
No vaccinations have been discontinued because of side effects of the vaccine. Although side effects were more frequent among women who received Gardasil ™ than in those who received placebo, it was mostly a slight discomfort at the injection site. These results confirm previous studies conducted on a smaller number of women.
The first preventive vaccine against virus responsible for most cancers of the uterus is now available in France. His name Gardasil. Marketed by Sanofi Pasteur MSD, it targets the human papillomavirus types 6, 11, 16 and 18, transmitted through sex and responsible to them four 70 to 84% of cancers of the cervix.
"Our recommendation would be to vaccinate young girls between 11 and 12 years to catch up for 13-26 years," said the laboratory. The vaccine has indeed its maximum effectiveness when given before the first contact with the virus. Each year, cancer of the cervix uteri kills more than 1 000 women in France. So far, only passed its prevention by screening.
The vaccine Gardasil was launched without awaiting the recommendations of the government The latter would obviously prefer that Sanofi Pasteur await the completion of negotiations on the management of vaccine before starting its marketing.
Indeed, several unknowns remain: according to DGS, "first, this vaccine only protects against certain strains of HPV that can lead to female genital cancers (80%) and secondly, even ifstudies conducted by Sanofi has shown that the vaccine prevented the appearance of histological lesions of high grade, we do not know today the term of protection granted, gold, cancers occur several years after infection.
According to the data showing that about 3% of girls in France have their first sexual intercourse before age 15, the Superior Council for Public Health of France (CHSPF) recommends the vaccination of girls aged 14 years and proposes to the 15-23 year old who have not yet had sexual intercourse or later in the year following their first report.
There are every year and 258 000 deaths worldwide, including 1 000 in France. Papillomaviruses present in 80% cases do not have the same carcinogenic. The most harmful is undoubtedly that of type 16 (HPV-16), implicated in 50 to 60% of cancers of the cervix. Comes second, HPV-18 which is responsible for 10% of cancers col2. Conversely, the risk of cancer among women not infected is virtually nil.
Only downside to the strategy of Pap smear screening, it involves a large number of reviews that benefit only a minority. Indeed, a maximum of 3% of women with HPV will develop cancer. Thus the development of an effective vaccine could soon lead to another prevention strategy.
A 100% protection - On September 20, 2006, the vaccine Gardasil received its European approval for placing on the market. This vaccine protects against human papillomavirus types 6, 11, 16 and 18 ,HPV 6 and 11 cause 90% of genital warts, sexually transmitted infections better known under the name of cockscomb. Several studies have measured the effectiveness of the vaccine, the principal has involved more than 12 000 women aged 16 to 26 years who were not infected by the virus.
Half received three doses of the vaccine and half received a placebo (inactive drug).After 17 months of follow-up, the first group showed no pre-cancerous lesions while they were 21 in the second group. Then, the principal investigator of the group Research on HPV at Washington University in Seattle.
No vaccinations have been discontinued because of side effects of the vaccine. Although side effects were more frequent among women who received Gardasil ™ than in those who received placebo, it was mostly a slight discomfort at the injection site. These results confirm previous studies conducted on a smaller number of women.
The first preventive vaccine against virus responsible for most cancers of the uterus is now available in France. His name Gardasil. Marketed by Sanofi Pasteur MSD, it targets the human papillomavirus types 6, 11, 16 and 18, transmitted through sex and responsible to them four 70 to 84% of cancers of the cervix.
"Our recommendation would be to vaccinate young girls between 11 and 12 years to catch up for 13-26 years," said the laboratory. The vaccine has indeed its maximum effectiveness when given before the first contact with the virus. Each year, cancer of the cervix uteri kills more than 1 000 women in France. So far, only passed its prevention by screening.
The vaccine Gardasil was launched without awaiting the recommendations of the government The latter would obviously prefer that Sanofi Pasteur await the completion of negotiations on the management of vaccine before starting its marketing.
Indeed, several unknowns remain: according to DGS, "first, this vaccine only protects against certain strains of HPV that can lead to female genital cancers (80%) and secondly, even ifstudies conducted by Sanofi has shown that the vaccine prevented the appearance of histological lesions of high grade, we do not know today the term of protection granted, gold, cancers occur several years after infection.
According to the data showing that about 3% of girls in France have their first sexual intercourse before age 15, the Superior Council for Public Health of France (CHSPF) recommends the vaccination of girls aged 14 years and proposes to the 15-23 year old who have not yet had sexual intercourse or later in the year following their first report.
If you liked this post, subscribe to our blog by filling your e-mail address below:
Want to add something? Post your comments